SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference
SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference
STAMFORD, Conn., May 08, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that management will participate in a fireside chat at the BofA Securities 2024 Health Care Conference, taking place in Las Vegas, Nevada on Tuesday, May 14, 2024 at 3:40 p.m. PT / 6:40 p.m. ET.
康涅狄格州斯坦福，2024年5月8日（GLOBE NEWSWIRE）——專注於嚴重罕見疾病和癌症的商業階段生物製藥公司SpringWorks Therapeutics, Inc.（納斯達克股票代碼：SWTX）今天宣佈，管理層將參加太平洋時間2024年5月14日星期二下午3點40分在內華達州拉斯維加斯舉行的美國銀行證券2024年醫療保健會議的爐邊談話美國東部時間下午
To access the live webcast, please visit the Events & Presentations page within the Investors & Media section of the company's website at A replay of the webcast will be available on SpringWorks' website for a limited time following the conference.
要觀看網絡直播，請訪問公司網站 “投資者與媒體” 部分中的 “活動和演講” 頁面。會議結束後，網絡直播的重播將在SpringWorks的限定時間內在SpringWorks的網站上播出。
About SpringWorks Therapeutics
關於 SpringWorks 治療公司
SpringWorks is a commercial-stage biopharmaceutical company applying a precision medicine approach to developing and delivering life-changing medicines for people with severe rare diseases and cancer.
SpringWorks是一家處於商業階段的生物製藥公司，採用精準醫療方法爲患有嚴重罕見疾病和癌症的人開發和提供改變生活的藥物。
Founded in 2017, SpringWorks has a diversified targeted oncology pipeline spanning solid tumors and hematological cancers, including clinical trials in rare tumor types and highly prevalent, genetically defined cancers. OGSIVEO, approved in the United States for the treatment of adult patients with progressing desmoid tumors who require systemic treatment, is SpringWorks' first FDA-approved therapy. SpringWorks' strategic approach and operational excellence in clinical development have enabled it to rapidly advance its lead product candidates into late-stage trials and enter into multiple collaborations with innovators in industry and academia to unlock the full potential for its portfolio and create more solutions for patients with cancer.
SpringWorks成立於2017年，擁有多元化的靶向腫瘤產品線，涵蓋實體瘤和血液系統癌，包括針對罕見腫瘤類型和高度流行的基因定義癌症的臨床試驗。OGSIVEO是SpringWorks首款經美國食品藥品管理局批准的療法，已獲美國批准用於治療需要全身治療的硬結腫瘤進展的成年患者。SpringWorks的戰略方針和臨床開發方面的卓越運營使其能夠迅速將其主要候選產品推向後期試驗，並與行業和學術界的創新者進行多次合作，以釋放其產品組合的全部潛力，爲癌症患者創造更多解決方案。
For more information, visit and follow @SpringWorksTx on X (formerly Twitter), LinkedIn, and YouTube.
欲了解更多信息，請訪問 然後關注 @SpringWorksTx 在 X（前身爲 Twitter）上， 領英，以及 優酷。
Contacts:
Kim Diamond
Vice President, Communications and Investor Relations
Phone: 203-561-1646
Email: kdiamond@springworkstx.com
聯繫人：
金戴蒙德
傳播與投資者關係副總裁
電話：203-561-1646
電子郵件： kdiamond@springworkstx.com
Samantha Hilson Sandler
Senior Director, Investor Relations
Phone: 203-461-5501
Email: samantha.sandler@springworkstx.com
薩曼莎·希爾森·桑德勒
投資者關係高級董事
電話：203-461-5501
電子郵件： samantha.sandler@springworkstx.com